000070651 001__ 70651
000070651 005__ 20210618112019.0
000070651 0247_ $$2doi$$a10.1530/JOE-16-0117
000070651 0248_ $$2sideral$$a106024
000070651 037__ $$aART-2016-106024
000070651 041__ $$aeng
000070651 100__ $$0(orcid)0000-0003-3957-3749$$aEsteban-Zubero, E.
000070651 245__ $$aPotential benefits of melatonin in organ transplantation: a review
000070651 260__ $$c2016
000070651 5060_ $$aAccess copy available to the general public$$fUnrestricted
000070651 5203_ $$aOrgan transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemia-reperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acid L-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.
000070651 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000070651 590__ $$a4.706$$b2016
000070651 591__ $$aENDOCRINOLOGY & METABOLISM$$b26 / 138 = 0.188$$c2016$$dQ1$$eT1
000070651 592__ $$a2.013$$b2016
000070651 593__ $$aEndocrinology, Diabetes and Metabolism$$c2016$$dQ1
000070651 593__ $$aEndocrinology$$c2016$$dQ1
000070651 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000070651 700__ $$0(orcid)0000-0002-8275-7191$$aGarcia-Gil, F.A.$$uUniversidad de Zaragoza
000070651 700__ $$0(orcid)0000-0002-2455-680X$$aLopez-Pingarron, L.$$uUniversidad de Zaragoza
000070651 700__ $$aAlatorre-Jimenez, M.A.
000070651 700__ $$0(orcid)0000-0003-1420-5499$$aIñnigo-Gil, P.$$uUniversidad de Zaragoza
000070651 700__ $$aTan, D.X.
000070651 700__ $$0(orcid)0000-0001-9507-6478$$aGarcia, J.J.$$uUniversidad de Zaragoza
000070651 700__ $$aReiter, R.J.
000070651 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000070651 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000070651 7102_ $$11004$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Cirugía
000070651 773__ $$g229, 3 (2016), R129-R146$$pJ. Endocrinol.$$tJOURNAL OF ENDOCRINOLOGY$$x0022-0795
000070651 8564_ $$s748505$$uhttps://zaguan.unizar.es/record/70651/files/texto_completo.pdf$$yVersión publicada
000070651 8564_ $$s101527$$uhttps://zaguan.unizar.es/record/70651/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000070651 909CO $$ooai:zaguan.unizar.es:70651$$particulos$$pdriver
000070651 951__ $$a2021-06-18-11:14:33
000070651 980__ $$aARTICLE